Onconetix (ONCO) Stock Price, News & Analysis

Company Overview

Onconetix, Inc. is a biotechnology company focused on developing and commercializing products for men’s health and oncology. The company’s activities center on therapies and diagnostic technologies intended to address conditions affecting the prostate and related areas of healthcare.

Onconetix’s lead commercial product is ENTADFI, an oral combination of tadalafil and finasteride approved by the U.S. Food and Drug Administration for the treatment of the signs and symptoms of benign prostatic hyperplasia, or BPH, in men with an enlarged prostate. Tadalafil may help improve urinary symptoms, while finasteride is intended to reduce prostate size over time.

The company was formerly known as Blue Water Vaccines and adopted the Onconetix name as its business strategy shifted toward men’s health and oncology. Its operations and commercial focus are primarily directed toward the United States. Information about additional products, geographic expansion and current leadership may change as the company develops its pipeline and commercialization strategy.

Key Stats

• Today's Range: $0.70 to $0.78
• 50-Day Range: $0.61 to $1.11
• 52-Week Range: $0.59 to $209.50
• Volume: 808,384 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $3.23 million
• P/E Ratio: 0.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Onconetix Stock Analysis - MarketRank™

Onconetix scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Onconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Onconetix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.60.

Price to Book Value per Share Ratio

Onconetix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.10% of the float of Onconetix has been sold short.

Short Interest Ratio / Days to Cover

Onconetix has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Onconetix has recently decreased by 19.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Onconetix does not currently pay a dividend.

Dividend Growth

Onconetix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.36

News Sentiment

Onconetix has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Onconetix this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for ONCO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

1 people have added Onconetix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Onconetix insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.27% of the stock of Onconetix is held by insiders.

Percentage Held by Institutions

23.89% of the stock of Onconetix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ONCO
• Previous Symbol: NASDAQ:ONCO
• CIK: 1782107
• Web: www.onconetix.com
• Phone: 513-620-4101
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $248.12
• Trailing P/E Ratio: 0.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.03 million
• Net Margins: -1,575.89%
• Pretax Margin: -1,575.89%
• Return on Equity: -91.95%
• Return on Assets: -53.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.21
• Quick Ratio: 2.14

Sales & Book Value

• Annual Sales: $810 thousand
• Price / Sales: 3.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $505.29 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 4,380,000
• Free Float: 4,368,000
• Market Cap: $3.23 million
• Optionable: N/A
• Beta: 2.68